glp-1 clinical studies efficacy results from clinical trials comparing different clinical trial glp 1 GLP-1R

Echocardiographic studies demonstrate that GLP-1 agonists improve global longitudinal strain, an early marker of subclinical diabetic cardiomyopathy, by 1520% [79]

It only means that the FDA wants more definitive long-term data

Given that the first published case report appeared only recently, and that epidemiological studies are still emerging, a label update may follow as more data accumulates

Both Eli Lilly and Novo Nordisk have been struggling to produce enough GLP-1 drugs to meet rising demand

But it's not the end of the road

GLP-1 medications help regulate appetite and slow how quickly food moves through the stomach